BioMarin Pharmaceuticals BMRN ROCTAVIAN — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's roctavian — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's ROCTAVIAN — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported ROCTAVIAN — total revenues of $2.64M in Q1 2026.
- How has BioMarin Pharmaceuticals's ROCTAVIAN — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's ROCTAVIAN — total revenues decreased by 74.9% year-over-year, from $10.51M to $2.64M.
- What does ROCTAVIAN — total revenues mean?
- The total sales revenue generated by a specific gene therapy product.
- How do you interpret ROCTAVIAN — total revenues?
- An increase indicates successful market penetration, expanded patient access, and effective commercial execution for the therapy. A decrease may signal competitive pressure, regulatory hurdles, or challenges in patient identification and reimbursement.
- How does ROCTAVIAN — total revenues compare across companies?
- Comparable to product-specific revenue metrics for specialty pharmaceuticals or gene therapy assets at peer biotechnology companies.